Cellosaurus logo
expasy logo

Cellosaurus GI-ME-N (CVCL_1232)

[Text version]
Cell line name GI-ME-N
Synonyms Gi-ME-N; Gi-MEN; GIMEN; Gimen; Gimen1; Gaslini Institute-ME-Neuroblastoma
Accession CVCL_1232
Resource Identification Initiative To cite this cell line use: GI-ME-N (RRID:CVCL_1232)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~25 hours (CLS=300179); ~24 hours (DSMZ=ACC-654).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (PubMed=20655465).
  • Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (PubMed=20655465).
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.42
East Asian, North0.23
East Asian, South0
South Asian7.63
European, North34.54
European, South55.82
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
Sex of cell Female
Age at sampling 3Y6M
Category Cancer cell line
STR profile Source(s): CLS; Cosmic-CLP; DepMap; DSMZ

D8S117910,14 (DepMap)
11,15 (DSMZ)
D13S3178,12 (Cosmic-CLP; DepMap; DSMZ)
12 (CLS)
Penta D9,13
Penta E15,20 (DepMap)
15,21 (DSMZ)

Run an STR similarity search on this cell line

Melodia A., Cornara L., Bertelli R., Canepa M., Gimelli G., Repetto G., Cornaglia-Ferraris P.
New line of human neuroblastoma derived from bone marrow.
Pathologica 78:371-384(1986)

PubMed=3204111; DOI=10.1007/BF00398190
Longo L., Christiansen H., Christiansen N.M., Cornaglia-Ferraris P., Lampert F.
N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization.
J. Cancer Res. Clin. Oncol. 114:636-640(1988)

Ponzoni M., Melodia A., Cirillo C., Casalaro A., Cornaglia-Ferraris P.
Effect of cytosine arabinoside on the growth and phenotypic expression of GI-ME-N, a new human neuroblastoma cell line.
Prog. Clin. Biol. Res. 271:437-448(1988)

PubMed=3422578; DOI=10.1016/0165-4608(88)90188-4
Donti E., Longo L., Tonini G.P., Verdona G., Melodia A., Lanino E., Cornaglia-Ferraris P.
Cytogenetic and molecular study of two human neuroblastoma cell lines.
Cancer Genet. Cytogenet. 30:225-231(1988)

PubMed=2535035; DOI=10.1002/gcc.2870010111
Martinsson T., Weith A., Cziepluch C., Schwab M.
Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region.
Genes Chromosomes Cancer 1:67-78(1989)

PubMed=2917605; DOI=10.1016/0014-4827(89)90196-1
Ponzoni M., Lanciotti M., Melodia A., Casalaro A., Cornaglia-Ferraris P.
Morphologic and phenotypic changes of human neuroblastoma cells in culture induced by cytosine arabinoside.
Exp. Cell Res. 181:226-237(1989)

PubMed=2296463; DOI=10.1203/00006450-199001000-00001
Cornaglia-Ferraris P., Ponzoni M., Montaldo P., Mariottini G.L., Donti E., Di Martino D., Tonini G.P.
A new human highly tumorigenic neuroblastoma cell line with undetectable expression of N-myc.
Pediatr. Res. 27:1-6(1990)

Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)

PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997)

PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5
Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R., van der Drift P., Chan A., Versteeg R., Speleman F.
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
Eur. J. Cancer 33:1974-1978(1997)

Thiele C.J.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)

PubMed=17506115; DOI=10.1002/nbm.1181
Peet A.C., McConville C.M., Wilson M.P., Levine B.A., Reed M., Dyer S.A., Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.
1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines.
NMR Biomed. 20:692-700(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) CLS; 300179
ICLC; HTL98011
Cell line databases/resources CLO; CLO_0003494
CLDB; cl1464
CLDB; cl4931
cancercelllines; CVCL_1232
Cell_Model_Passport; SIDM00227
Cosmic-CLP; 906872
DepMap; ACH-001344
DSMZCellDive; ACC-654
Anatomy/cell type resources BTO; BTO:0005808
Biological sample resources BioSample; SAMN03473467
Chemistry resources ChEMBL-Cells; CHEMBL3308868
ChEMBL-Targets; CHEMBL2366074
GDSC; 906872
PharmacoDB; GIMEN_405_2019
PubChem_Cell_line; CVCL_1232
Encyclopedic resources Wikidata; Q54835813
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM692856
GEO; GSM1669810
GEO; GSM3145705
Polymorphism and mutation databases Cosmic; 755616
Cosmic; 906872
Cosmic; 1167992
Cosmic; 1518065
Cosmic; 1526625
Cosmic; 1543771
Cosmic; 2239471
IARC_TP53; 27693
IARC_TP53; 23838
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number38